Ranbaxy Laboratories has reported results for second quarter ended September 30, 2014.
The company has reported a net loss of Rs 368.26 crore for the quarter under review as compared to a net loss of Rs 842.23 crore for the same quarter in the previous year. Total income of the company has decreased 8.92% at Rs 1338.93 crore for Q2FY15 as compared Rs 1470.19 crore for the corresponding quarter previous year.
On consolidated basis, the company has posted a net profit after taxes and minority interest of Rs 477.76 crore for the quarter as against a net loss of Rs 454.17 crore in the September quarter of previous fiscal. The company’s total income has increased by 15.92% at Rs 3277.88 crore for the quarter from Rs 2827.73 crore in the similar quarter of previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1652.75 |
| Dr. Reddys Lab | 1215.90 |
| Cipla | 1229.55 |
| Zydus Lifesciences | 927.75 |
| Lupin | 2309.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: